Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    ALT-836
Show Display Options
Rank Status Study
1 Completed A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Conditions: Locally Advanced Malignant Neoplasm;   Malignant Solid Tumour
Intervention: Biological: ALT-836 in combination with gemcitabine
2 Completed Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Conditions: Sepsis;   Acute Lung Injury;   Acute Respiratory Distress Syndrome
Interventions: Drug: ALT-836;   Drug: Placebo
3 Completed Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Conditions: Sepsis;   Acute Lung Injury;   Acute Respiratory Distress Syndrome
Interventions: Biological: TNX-832;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.